Claude-written reviews of research on post-acute infection syndromes

Each paper is reviewed against a published guide, graded out of 10, and summarised by its main strengths and weaknesses.

5/ 10Borderline
4.0 (1)No comments
Muscle abnormalities worsen after post-exertional malaise in long COVID
Appelman B, Charlton BT, Goulding RP, et al. · Nature Communications · 2024
Patients' muscle differed from that of recovered, more active controls at baseline, but the claim that abnormalities worsen after post-exertional malaise is mostly unsupported: most changes were shared with controls or never tested between groups.
Muscle damage claims lack the between-group testTissue scoring yes/no, blinding to time point unclearControls did the same exercise test and biopsies
6/ 10Borderline
No comments
Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia: A quantitative, controlled study using Doppler echography
van Campen CLMC, Verheugt FWA, Rowe PC, et al. · Clinical Neurophysiology Practice · 2020
Brain blood flow fell much more on tilt in patients than in healthy controls, even with normal heart rate and blood pressure, but without inactive or ill controls or a correction for over-breathing, the claims about cause and diagnosis go beyond the data.
Healthy controls only, fitness not reportedScans recorded by a clinician who knew the groupsMeasures blood volume to the brain, not just speed
4.5/ 10Fails
No comments
The DePaul Symptom Questionnaire-2: A Validation Study
Bedree H, Sunnquist M, Jason LA · Fatigue: Biomedicine, Health & Behavior · 2019
A sensible revision of a patient questionnaire, honestly described, but with no comparison group, no reference diagnosis and no repeat testing it cannot show the validity and reliability its title and conclusion claim.
No comparison group or reference diagnosisMore people meeting criteria is built into the designSplitting two-in-one questions shows clear differences
4/ 10Fails
3.0 (1)No comments
Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch® 3-dimensional genomic regulatory immuno-genetic profiling
Hunter E, Alshaker H, Bundock O, et al. · Journal of Translational Medicine · 2025
An interesting DNA-folding signal, but cases and most controls came from different sources, so the 96% accuracy may partly reflect sample origin rather than disease.
Cases and most controls from different sourcesSample counts inconsistent across the paperMarker selection confined to the training set
5/ 10Borderline
No comments
A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity
Kedor C, Freitag H, Meyer-Arndt L, et al. · Nature Communications · 2022
Careful early evidence that some people meet strict ME/CFS criteria after mild COVID-19, but the headline blood-marker links to grip strength appear to pool men and women, and most weaken or vanish in women alone.
Self-referred patients; cannot show how commonNo healthy or recovered controls measuredStrict criteria, with a real medical work-up
UnconvincingPreliminary
No comments
ADDRESS-LC: phase 2 trial of bezisterim for neurological symptoms of long COVID (topline results)
BioVie Inc. · Company press release and investor presentation · 2026
Bezisterim did not clearly beat placebo on any of 22 measures across the whole trial; the reported benefits come from unadjusted, selectively shown subgroups, so they are a hypothesis for a new trial, not evidence the drug works.
No measure improved clearly in the whole trialBenefits only in subgroups, uncorrected for many testsRandomised, blinded, placebo-controlled, 203 patients
4/ 10Fails
No comments
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial
White PD, Goldsmith KA, Johnson AL, et al. · The Lancet · 2011
A large, well-run trial whose gains rest on questionnaires filled in by patients who knew their treatment, while fitness, work and benefits did not improve; it cannot show that talking therapy or graded exercise changed the illness rather than how it was reported.
Main outcomes self-rated by unblinded patientsFitness, work and benefits did not improveLarge, properly randomised, very few dropouts
6.5/ 10Solid
No comments
Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome
DecodeME, Boutin T, Bretherick AD, et al. · medRxiv · 2025 Preprint
A large, careful genetics study with probable real findings; no valid cohort yet exists to replicate them, and the framing outruns that.
Artefact risk rests on internal checks aloneCases and controls genotyped apart, unequal checksLargest ME/CFS genetics study; 15,579 cases
3.5/ 10Fails
No comments
Effect of subcutaneous lidocaine–hydroxypropyl-β-cyclodextrin on quality of life in patients with post-COVID condition
Oostwouder CJ, Vos K, Lutke Schipholt IJ, et al. · eClinicalMedicine · 2024
No control group, no blinding and only subjective outcomes, so the reported improvement cannot be separated from placebo, regression to the mean or natural recovery.
No control groupCompletely unblindedSample size adequate for the design